Suppr超能文献

切除的无功能垂体腺瘤的影像学检查:监测的成本

Imaging of Resected Nonfunctioning Pituitary Adenomas: The Cost of Surveillance.

作者信息

Kistka Heather M, Kasl Rebecca A, Nayeri Arash, Utz Andrea L, Weaver Kyle D, Chambless Lola B

机构信息

Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, United States.

Vanderbilt University School of Medicine, Nashville, Tennessee, United States.

出版信息

J Neurol Surg B Skull Base. 2015 Sep;76(5):344-50. doi: 10.1055/s-0035-1549307. Epub 2015 May 8.

Abstract

Objectives To determine the cost of annual magnetic resonance imaging (MRI) surveillance after resection of nonfunctioning pituitary adenomas (NFPAs) and its effectiveness in reducing visual compromise due to tumor recurrence. Design Retrospective case series. Setting Vanderbilt University Medical Center (2003-2011). Participants A total of 120 patients underwent primary transsphenoidal resection and surveillance of NFPAs between 2003 and 2011. Main Outcome Measures Time from initial surgery to most recent imaging or progression. Surveillance MRI costs according to Centers for Medicare and Medicaid database and visual field deficits. Results Patients received 382 surveillance scans at a total cost of $218,477.30. The median follow-up was 47 months (interquartile range [IQR]: 26-76), and the median interval between scans was 357 days (IQR: 225-434). Overall, 50 scans (13%) revealed tumor growth. The cost per scan revealing growth was $4,369.55. The cost to identify 19 patients (16%) with clinically significant growth was $11,498.80 per patient. A total of 5 of 19 patients (26%) experienced new visual deficits prior to intervention. Patients with visual decline tended to have longer scan intervals than those with preserved vision (mean: 239 versus 794 days; p = 0.0584). No patient with annual surveillance imaging experienced visual decline. Conclusions Annual MRI scans are a sensitive and cost-conscious method to identify NFPA recurrence prior to visual decline.

摘要

目的

确定无功能垂体腺瘤(NFPA)切除术后每年进行磁共振成像(MRI)监测的成本及其在减少因肿瘤复发导致的视力损害方面的有效性。

设计

回顾性病例系列研究。

地点

范德比尔特大学医学中心(2003 - 2011年)。

参与者

2003年至2011年间,共有120例患者接受了NFPA的初次经蝶窦切除术及监测。

主要观察指标

从初次手术到最近一次成像或病情进展的时间。根据医疗保险和医疗补助服务中心数据库得出的监测MRI成本以及视野缺损情况。

结果

患者共接受了382次监测扫描,总成本为218,477.30美元。中位随访时间为47个月(四分位间距[IQR]:26 - 76),扫描的中位间隔时间为357天(IQR:225 - 434)。总体而言,50次扫描(13%)显示肿瘤生长。每次显示肿瘤生长的扫描成本为4,369.55美元。识别出19例(16%)有临床显著生长的患者的成本为每位患者11,498.80美元。19例患者中有5例(26%)在干预前出现了新的视力缺损。视力下降的患者扫描间隔往往比视力未受损的患者更长(平均:239天对794天;p = 0.0584)。接受年度监测成像的患者均未出现视力下降。

结论

每年进行MRI扫描是一种在视力下降前识别NFPA复发的敏感且具有成本效益的方法。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验